Copaxone 40 mg 3 Times a Week FDA-Approved
Tired of daily Copaxone 20 mg injections for multiple sclerosis? A new option is now available. FDA just approved 40 mg dose three times a week.
The GALA trial studied Copaxone 40 mg (double dose) three times a week vs. placebo in 1404 patients. Copaxone 40 mg three times a week reduced new relapses 34% and reduced MRI activity with contrast 45%. Safety of Copaxone 40 mg appears comparable to 20 mg dose. In fact, a lower amount of immediate post-injection reactions were seen in the GALA 40 mg trial. Previous studies had demonstrated a 29% reduction of relapses with Copaxone 20 mg daily.
If interested in switching to 40 mg three times a week, discuss with your healthcare provider.
BY: Barry Singer, MD DATE: January 29, 2014 TOPIC: MS Research News